| Document |
Document Title |
|
WO/2022/116528A1 |
The present disclosure belongs to the technical fields of molecular biology and bioengineering, and relates to a circular RNA, a vaccine containing the circular RNA, and a kit for detecting a novel coronavirus neutralizing antibody. A re...
|
|
WO/2022/116952A1 |
An antigen-binding protein targeting CD70. In particular, the present invention relates to a chimeric antigen receptor containing the antigen binding protein and the use thereof, and cells containing or expressing the antigen binding pro...
|
|
WO/2022/116480A1 |
Provided are a trifunctional fusion protein containing a tumor-associated antigen (TAA) antibody, a TGF-β inhibitor, and a CD3 antibody, and an application thereof. By introducing a TGF-β inhibitor into antibody molecules, the trifunct...
|
|
WO/2022/110499A1 |
Disclosed are an application of a signal peptide in the expression of GLP-1 or a GLP-1 fusion protein. The amino acid sequence of the signal peptide is shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4. The signal peptide can...
|
|
WO/2022/109743A1 |
A fusion protein comprises a nanocage monomer or a subunit thereof linked to a DR4 and/or DR5 antigen-binding moiety, wherein a plurality of the fusion proteins self-assemble to form a nanocage. Also described is a nanocage comprising th...
|
|
WO/2022/111562A1 |
The present application relates to a fusion protein, and in particular to a modified immune cell containing the fusion protein and the use thereof. The fusion protein contains an antigen or a functionally active fragment thereof, a co-st...
|
|
WO/2022/110099A1 |
This disclosure relates to coronavirus vaccines and uses thereof. In one aspect, the disclosure provides a nucleic acid vaccine, comprising a sequence encoding a spike protein or fragment thereof derived from a coronavirus.
|
|
WO/2022/113075A1 |
Chimeric polypeptides comprising a first subunit comprising an antigen-binding domain, a second subunit comprising at least one immunogenic peptide comprising a signal peptide and a third subunit comprising a cleavable moiety, wherein th...
|
|
WO/2022/115864A1 |
Compositions and methods for treating diseases associated with expression of cluster differentiation 33 (CD33) and/or cluster differentiation 5 (CDS) are described. The compositions and methods relate to two chimeric antigen receptors (C...
|
|
WO/2022/111405A1 |
Provided in the present invention are an antibody targeting Claudin18.2, and a multispecific antibody, a chimeric antigen receptor, an antibody conjugate, a pharmaceutical composition and a kit comprising same, and the use thereof in the...
|
|
WO/2022/109023A1 |
This disclosure provides methods of treating cancer comprising administering effector cell engaging molecules comprising one or more tumor targeting moieties and one or more effector cell engaging moieties. For example, the effector cell...
|
|
WO/2022/105826A1 |
Provided are an NKG2A-targeting antibody, and a multispecific antibody, a chimeric receptor, an antibody conjugate, a pharmaceutical composition and a kit which comprise same, and the use thereof in the diagnosis/treatment/prevention of ...
|
|
WO/2022/105811A1 |
Provided are a humanized CD19 antibody and the use thereof. Specifically, provided are an antibody- or antigen-binding fragment capable of binding to CD19, a multi-specific antigen binding molecule, a chimeric antigen receptor, an immune...
|
|
WO/2022/105880A1 |
A fusion gene, a recombinant novel coronavirus high-efficiency immune DNA vaccine, a construction method therefor and use thereof. The immune DNA vaccine ZD-nCor19 provided therein uses RBD protein, segment 301-538aa of the S2 subunit an...
|
|
WO/2022/105847A1 |
Provided are long-acting nerve growth factor (NGF) polypeptides comprising from N-terminus to C-terminus an NGF moiety and an Fc moiety, methods of making, and uses thereof.
|
|
WO/2022/105751A1 |
A new fusion protein including a PD-L1 antibody and a TGFβ receptor, a nucleic acid encoding the fusion protein or a fragment thereof, a host cell comprising same, and the relevant use. In addition, the present invention also relates to...
|
|
WO/2022/109399A1 |
The present disclosure provides Transforming Growth Factor Beta (TGF-β) polypeptide constructs and complexes that find use in, for example, therapeutic treatment of diseases including autoimmune diseases and metabolic diseases and disor...
|
|
WO/2022/109220A1 |
The present disclosure provides for methods, systems, and compositions of nucleic acid and peptide sequences. The present disclosure provides for a nucleic acid sequence encoding at least two amino acid sequences selected from the group ...
|
|
WO/2022/105190A1 |
Provided are an adenosine deaminase and a related biomaterial and application thereof. The adenosine deaminase is a protein having an amino acid sequence represented by positions 1-167 of a sequence 2 in a sequence list and is called Tad...
|
|
WO/2022/105879A1 |
Isolated anti-human B7-H3 antibody includes two heavy chains including a hinge region comprising an amino acid sequence that allows site-specific conjugation of cytotoxic drugs. Each heavy chain includes a human CH1 domain located upstre...
|
|
WO/2022/100303A1 |
The present application relates to a kit and method for detecting a SARS-CoV-2 neutralizing antibody. The present application relates to the field of biological medicine, and provided are a kit and method for detecting a SARS-CoV-2 neutr...
|
|
WO/2022/101463A1 |
Apoptosis is the main mechanism by which Mosquito-borne Zika virus infection causes cell death. Here, the inventors aimed to determine whether the last C-terminal residues M31/41 of ZIKV M ectodomain can trigger apoptotic cell death. Apo...
|
|
WO/2022/101907A1 |
Provided herein are conjugates of retrograde tracers and cell-deactivating agents useful in targeting the nerve cells' body (soma) of neurons that are associated with pain, spasm or tonus, as well as methods of controllable selective dea...
|
|
WO/2022/100555A1 |
Provided are CD164 mucin domain fusion proteins with a heterologous protein, such as a heterologous protein with a therapeutic function and can benefit from extended serum half-life. Methods of using the fusion proteins are also provided.
|
|
WO/2022/099695A1 |
Provided are CD164 mucin domain fusion proteins with a heterologous protein, such as a heterologous protein with a therapeutic function and can benefit from extended serum half-life. Methods of using the fusion proteins are also provided.
|
|
WO/2022/100585A1 |
Provided are an anti-Her-2 antibody-chemokine fusion protein, a preparation method therefor and an application thereof. Specifically, provided is a fusion protein, the fusion protein comprising an anti-Her-2 antibody or an active fragmen...
|
|
WO/2022/100741A1 |
Provided is a fusion protein of human serum albumin or a wild type thereof and human interleukin-2 or a mutation thereof, said fusion protein has a significantly extended in vivo half-life relative to recombinant interleukin-2, can be us...
|
|
WO/2022/099963A1 |
Provided by the present invention are a fusion protein for improving the oral administration stability of a polypeptide drug, and an application thereof. The fusion protein of the present invention contains β-mannanase, a linker peptide...
|
|
WO/2022/095916A1 |
The present invention relates to the field of biotechnologies, and in particular, to a cell surface macromolecular quantitative display system, a preparation method therefor and use thereof. The cell surface macromolecular quantitative d...
|
|
WO/2022/095803A1 |
The present invention provides a CD7-targeting humanized antibody, and a multispecific antibody, chimeric antigen receptor, antibody conjugate, pharmaceutical composition, and kit comprising the CD7-targeting humanized antibody, and a us...
|
|
WO/2022/097663A1 |
It is found that four nuclease domain variants according to the present invention have nuclease activity superior to that of a wild type nuclease domain, and it is possible to improve genome editing efficiency in a combination of various...
|
|
WO/2022/098570A1 |
This invention disclosure describes novel polypeptide antagonists capable of neutralizing multiple members of TGF-β family in a selective manner. Specifically, the multispecific polypeptide antagonists disclosed herein comprise at least...
|
|
WO/2022/097047A1 |
This disclosure relates to methods of treating cancers in a human patient (e.g., Multiple myeloma (MM)) comprising administration of an antibody-drug conjugate (ADC) comprising a monoclonal antibody, or an antigen-binding fragment thereo...
|
|
WO/2022/099287A1 |
The present disclosure provides methods for improving the preparation efficiency of genetically modified immune cells and improving the quality of immune cells.
|
|
WO/2022/097750A1 |
The present invention addresses the problem of providing a novel chimeric antigen receptor. The problem can be solved by a chimeric antigen receptor which includes an antigen-binding domain, a transmembrane domain, and an intracellular s...
|
|
WO/2022/094721A1 |
Described herein is an anti-class II MHC antibody fused to a SARS-CoV-2 antigen. Also described is a vaccine comprising the antibody and methods for treating and/or preventing SARS-CoV-2, wherein the methods comprise administering the an...
|
|
WO/2022/095926A1 |
The present application provides an antibody targeting interleukin 36R, a preparation method therefor, and an application thereof. Specifically, the present application provides an IL-36R antibody having high affinity and high bioactivit...
|
|
WO/2022/099065A1 |
Disclosed are compositions and methods related to the construction and use of conditional universal synthetic notch (synNotch) receptors and conditional chimeric antigen receptor (CAR) T cells. Also disclosed herein are methods of using ...
|
|
WO/2022/098797A1 |
In various embodiments, the present disclosure provides chimeric antigen receptors (CARs) which bind to mesothelin. The mesothelin CARs comprise an extracellular region comprising a binding domain that specifically binds to at least a po...
|
|
WO/2022/098903A1 |
The present disclosure generally relates to, inter alia, methods, kits, and systems for the diagnosis and/or treating various health conditions, such as proliferative disorders (e.g., cancers), associated with a decreased level or a loss...
|
|
WO/2022/089353A1 |
Provided in the present invention are a BCMA-targeting single-domain antibody and an encoding nucleotide sequence thereof. Also provided in the present invention are a multispecific antibody, a chimeric antigen receptor, and an antibody ...
|
|
WO/2022/093333A1 |
The present invention relates to recombinant T-cell receptors that bind specifically, in a MHC restricted manner, to a particular epitope present in the shared cancer-testis antigen known as NY-ESO-1 and/or a particular epitope present i...
|
|
WO/2022/089471A1 |
Provided are a β-coronavirus multimeric antigen, a preparation method therefor and an application thereof, the amino acid sequence of the β-coronavirus multimeric antigen comprising: some amino acid sequences or all amino acid sequence...
|
|
WO/2022/089601A1 |
Provided in the present invention are a bifunctional fusion protein consisting of IL-2 and an antibody subunit, and the use thereof in the preparation of an anti-tumor drug. The bifunctional fusion protein comprises a heterodimer or a ho...
|
|
WO/2022/092132A1 |
Provided is a peptide having the following sequence and comprising 3-8 amino acid residues. (I): XmZnPUq Here, P is proline; Z represents an amino acid residue independently selected from lysine (K) and asparagine (N); X represents an ...
|
|
WO/2022/089569A1 |
The present invention provides an engineered chimeric soluble T cell receptor (ETCR), which comprises (i) all or part of TCR α chain, fused to all or part of the antibody constant domain, and (ii) all or part of TCR β chain, fused to a...
|
|
WO/2022/088953A1 |
The present invention provides a SARS-CoV-2 RBD conjugated nanoparticle vaccine, comprising: a) a nanoparticle carrier obtained by self-assembly of a carrier protein expressed in fusion with SpyCatcher; b) RBD antigen of SARS-CoV-2 virus...
|
|
WO/2022/089557A1 |
Provided is a use of a regulator of ITPRIPL1 in the preparation of a drug that regulates immune responses or fights tumors, the regulator being used to increase or decrease the expression or function of the ITPRIPL1 gene or protein in an...
|
|
WO/2022/094237A1 |
Disclosed herein are therapeutic conjugates having an extended circulating serum half- life. The therapeutic conjugates comprise a drug moiety linked to a half-life extension moiety via an enzyme-cleavable linker. Methods of using the th...
|
|
WO/2022/093310A1 |
The present disclosure relates, inter alia, to compositions and methods, including heterodimeric proteins and chimeric proteins comprising portions of butyrophilin family of proteins that find use in the treatment of disease, such as imm...
|
